Avecho Advances Phase III CBD Trial Toward Interim Analysis Milestone
Avecho Biotechnology Limited (ASX: AVE) has provided an update on enrolment progress for its pivotal Phase III study evaluating its oral CBD TPM®-enhanced capsule as a potential treatment for insomnia. To date, 190 participants have received study medication, meaning the Company is nearing completion of recruitment for the interim analysis cohort, which is based on approximately 210 randomised patients. The remaining enrolment is expected to be completed in early 2026, after which Avecho will confirm the timing of the interim analysis.
The Company advised that recruitment has extended beyond earlier expectations due to the strict eligibility requirements applied, which are intended to ensure the trial population is optimally suited to assessing both efficacy and safety. Management believes this targeted approach materially improves the likelihood of achieving a robust and clinically meaningful outcome. Once recruitment concludes, Avecho will advance toward completing the interim analysis, with results anticipated to be available during the first half of 2026.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to this. Read our Privacy Policy and Terms & Conditions
Avecho Advances Phase III CBD Trial Toward Interim Analysis Milestone
Avecho Biotechnology Limited (ASX: AVE) has provided an update on enrolment progress for its pivotal Phase III study evaluating its oral CBD TPM®-enhanced capsule as a potential treatment for insomnia. To date, 190 participants have received study medication, meaning the Company is nearing completion of recruitment for the interim analysis cohort, which is based on approximately 210 randomised patients. The remaining enrolment is expected to be completed in early 2026, after which Avecho will confirm the timing of the interim analysis.
The Company advised that recruitment has extended beyond earlier expectations due to the strict eligibility requirements applied, which are intended to ensure the trial population is optimally suited to assessing both efficacy and safety. Management believes this targeted approach materially improves the likelihood of achieving a robust and clinically meaningful outcome. Once recruitment concludes, Avecho will advance toward completing the interim analysis, with results anticipated to be available during the first half of 2026.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au